Imugene Limited (IMU.AX)
Develops immunotherapy drugs to train patients' immune systems to fight cancer
0.09-0.01%Healthcare
StockGlow Score
Bearish
BearishBullish
1 year ago-66.0%
The outlook
Imugene is trading near its 52-week low, well below both its 50- and 200-day moving averages, signaling a weak near-term trend. Analyst coverage shows an average price target roughly 261% above the current price, though this sits against a broadly bearish sentiment score. The stock's current positioning reflects substantial downward pressure despite the gap between price and analyst targets.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range0% of the way from its 52-week low to high
Price targetAvg target +261% vs current price
Analyst price target
~12-month · 3 analysts0.31average target+260.8% vs now
Now 0.09
Low 0.24High 0.43
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$42.3M
52-wk high
0.46
52-wk low
0.09
50-day avg
0.10
200-day avg
0.22
Trailing P/E
—